SCHEMBL16631488

SCHEMBL16631488

O=c1[nH]c(=O)n([C@@H]2O[C@H](CO)C(O)[C@@H]2O)cc1-n1ccnn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYGM P11217 3/20 0.58
TK2 O00142 3/20 0.54
SLC28A1 O00337 1/20 0.53
SLC28A2 O43868 1/20 0.53
SLC29A1 Q99808 1/20 0.53
SLC28A3 Q9HAS3 1/20 0.53
MAPT P10636 1/20 0.48
CDA P32320 1/20 0.48
ADORA3 P0DMS8 1/20 0.46
ADORA1 P30542 1/20 0.46
DNPH1 O43598 1/20 0.44
P2RY2 P41231 1/20 0.44
LMNA P02545 1/20 0.43
THRB P10828 1/20 0.43
MTOR P42345 1/20 0.43
MDM2 Q00987 1/20 0.43
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
HPGD P15428 1/20 0.43
CD69 Q07108 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631490 0.82 PYGM (0.57) PYGMTK2SLC28A1SLC28A2SLC29A1
SCHEMBL16631594 0.81 PYGM (0.56) PYGMTK2SLC28A1SLC28A2SLC29A1
SCHEMBL18080027 0.81 P2RY6 (0.64) DNPH1P2RY2
SCHEMBL16631506 0.80 PYGM (0.55) PYGMTK2SLC28A1SLC28A2SLC29A1
SCHEMBL16631423 0.80 PYGM (0.55) PYGMTK2SLC28A1SLC28A2SLC29A1
SCHEMBL16631406 0.80 LMNA (0.56) MAPTCDAADORA3ADORA1LMNA
SCHEMBL5752366 0.78 PYGM (0.65) PYGMTK2SLC28A1SLC28A2SLC29A1
SCHEMBL2056641 0.76 PYGM (0.72) PYGMTK2SLC28A1SLC28A2SLC29A1
SCHEMBL18513005 0.76 PYGM (0.72) PYGMTK2SLC28A1SLC28A2SLC29A1
SCHEMBL14928850 0.76 PYGM (0.72) PYGMTK2SLC28A1SLC28A2SLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 PYGM 303/4885TK2 123/4885SLC28A1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.